Abnormal lipid and lipoprotein profiles in reumatoid arthritis
Keywords:
lipids, lipoproteins, oxidized LDL, rheumatoid arthritisAbstract
Patients with rheumatoid arthritis (RA) have a high mortality rate than the general population with cardiovascular disease resulting from accelerated atherosclerosis being the most common cause of death. Plasma lipoprotein levels are an important determinant of atherosclerosis, the major cause of coronary artery disease (CAD) and stroke. The study group consisted of 10 patients (27–78 years) with RA. The reference group was made up of 13 healthy subjects (22–52 years). The aim of the present study was to investigate lipid, lipoprotein, ox-LDL concentrations and lipid and lipoprotein ratios in RA patients and compared to healthy subjects. The serum levels of lipids and apoAI, apoB, and oxidized-LDL (ox-LDL) were determined. Lipid and lipoprotein profiles were obtained in serum after 14-hour overnight fasting. Lipids and lipoproteins (apoA, apoB) were determined on Hitachi 902 analyzer. LDL-cholesterol (LDL-C) was calculated according to the Friedewald formula. Non-HDL-cholesterol (non-HDL-C) was calculated as total cholesterol (TC) minus HDL-C. Ox-LDL concentration was made using the ELISA method from BioMedica, Vien, Austria. The obtained results in RA patients show that those had significantly increased TG, TC, LDL-C, non-HDL-C, apoB, ox-LDL concentrations and TG/HDL-C, TC/HDL-C, LDL-C/HDL-C ratios, and decreased HDL-C level and apoAI/apoB, HDL-C/apoAI ratios as compared to the reference group. Conclusion. Disturbances in lipid and lipoprotein profiles and high ox-LDL level suggest that RA patients have a high risk of arteriosclerosis. However, future studies are required.
References
1. Ansell B.J., Navab M., Kamranpour N et al.: Inflammatory/anti-inflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation, 108, 2751, 2003.
2. Allanore Y., Sellam J., Ekindjian O.G., Borderie D.: Effect of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. Clin. Chim. Acta, 365, 143, 2006.
3. Burger D., Dayer JM.: High-density lipoprotein-associated with apolipoprotein A-I: the missing link between infection and chronic inflammation? Autoimmun. Rev., 1, 111, 2002.
4. Cabana V.G., Siegel J.N., Sabesin S.M.: Effects of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins. J. Lipid Res., 30, 39, 1989.
5. Charles-Schoeman C., Watanabe J., Lee Y.Y. et al.: Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis & Rheumatism, 60, 2870, 2009.
6. Chen X., Xun K., Chen L., Wang Y.: TNF-α, a potent lipid metabolism regulator. Cell Biochem. Funct., 27, 407, 2009.
7. Del Rincon I., Williams K., Stern M.P. et al.: Association between carotid atherosclerosis and markers of inflammation in rheumathoid arthritis patients and healthy subjects. Arthritis Reum., 48, 1833, 2003.
8. Donahoo W.T., Kosmiski L.A., Eckel RH.: Drugs causing dyslipoproteinemia. Endocrinol. Metab. Clin. North. Am., 27, 677, 1998.
9. Friedewald W.T., Levy R.I., Friedrickson D.S.: Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin. Chem., 18, 499, 1972.
10. Garcia-Gomez C., Nolla J.M., Valverde J., et al.: Hihg HDL-cholesterol in women with rheumatoid arthritis on low-dose glucocorticoid therapy. Eur. J. Clin. Invest., 38, 686, 2008.
11. Gu L., Johnson M.W., Lius A.J.: Quantitative trait locus analysis of plasma lipoprotein levels in an autoimmune mouse model. Interactions between lipoprotein metabolism, autoimmune disease, and atherogenesis. Arterioscler. Thromb. Vasc. Biol., 19, 442, 1999.
12. Halm V.P, Nielen M.M.L, Nurmohamed M.T. et al.: Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann. Rheum. Dis., 66, 184, 2007.
13. Holvoet P., Mertens A., Verhamme P. et al.: Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol., 21, 844, 2001.
14. Hulthe J., Fagerberg B.: Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR Study). Atheroscler. Thromb. Vasc. Biol., 22, 1162, 2002.
15. Hyka N., Dayer JM., Modoux C. et al.: Apolipopprotein AI inhibits the production of interleukin -1 beta and tumor necrosis factor-alpha by bloking contact-mediated activation of monocytes by T lymphocytes. Blood, 97, 2381, 2001.
16. Mc Mahon M., Brahn E.: Inflammatory lipids as a target for therapy in the rheumatic diseases. Expert Opin. Invest. Drugs, 17, 1213, 2008.
17. Popa C., Netea M.G., Van der Meer J.V.M. et al.: Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann. Rheum. Dis., 66, 1503, 2007.
18. Seriolo B., Paolono S., Sulli A. et al.: Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis. Ann. N.Y. Acad. Sci., 1069, 414, 2006.
19. Wang J., Hu B., Meng Y. et al.: The level of malondialdehyde-modified LDL and LDL immune complexes in patients with rheumatoid arthritis. Clin. Biochem., 42, 1352, 2009.
20. Watson A.D., Navab M., Hama S.Y. et al.: Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J. Clin. Invest., 95, 774, 1995.
Downloads
Published
Issue
Section
License
Copyright (c) 2010 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
